vs
ICU MEDICAL INC（ICUI）与STERLING INFRASTRUCTURE, INC.（STRL）财务数据对比。点击上方公司名可切换其他公司
STERLING INFRASTRUCTURE, INC.的季度营收约是ICU MEDICAL INC的1.5倍（$825.7M vs $540.7M），STERLING INFRASTRUCTURE, INC.净利率更高（11.6% vs -2.9%，领先14.5%），STERLING INFRASTRUCTURE, INC.同比增速更快（91.6% vs -14.1%），过去两年STERLING INFRASTRUCTURE, INC.的营收复合增速更高（19.0% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
本公司是总部位于印度马哈拉施特拉邦孟买的跨国工程总承包（EPC）企业，业务覆盖可再生能源、数据中心、柴油发电、机电水暖（MEP）服务等多个领域，已在全球三十余个国家交付项目，执行团队遍布亚洲、中东、非洲、欧洲及澳大利亚。
ICUI vs STRL — 直观对比
营收规模更大
STRL
是对方的1.5倍
$540.7M
营收增速更快
STRL
高出105.7%
-14.1%
净利率更高
STRL
高出14.5%
-2.9%
两年增速更快
STRL
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $825.7M |
| 净利润 | $-15.7M | $96.0M |
| 毛利率 | 37.5% | 23.5% |
| 营业利润率 | 1.0% | 16.7% |
| 净利率 | -2.9% | 11.6% |
| 营收同比 | -14.1% | 91.6% |
| 净利润同比 | 34.0% | 143.1% |
| 每股收益（稀释后） | $-0.63 | $3.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUISTRL
| Q1 26 | — | $825.7M | ||
| Q4 25 | $540.7M | $755.6M | ||
| Q3 25 | $537.0M | $689.0M | ||
| Q2 25 | $548.9M | $614.5M | ||
| Q1 25 | $604.7M | $430.9M | ||
| Q4 24 | $629.8M | $498.8M | ||
| Q3 24 | $589.1M | $593.7M | ||
| Q2 24 | $596.5M | $582.8M |
净利润ICUISTRL
| Q1 26 | — | $96.0M | ||
| Q4 25 | $-15.7M | $87.6M | ||
| Q3 25 | $-3.4M | $92.1M | ||
| Q2 25 | $35.3M | $71.0M | ||
| Q1 25 | $-15.5M | $39.5M | ||
| Q4 24 | $-23.8M | $113.2M | ||
| Q3 24 | $-33.0M | $61.3M | ||
| Q2 24 | $-21.4M | $51.9M |
毛利率ICUISTRL
| Q1 26 | — | 23.5% | ||
| Q4 25 | 37.5% | 21.7% | ||
| Q3 25 | 37.4% | 24.7% | ||
| Q2 25 | 37.9% | 23.3% | ||
| Q1 25 | 34.7% | 22.0% | ||
| Q4 24 | 36.1% | 21.4% | ||
| Q3 24 | 34.8% | 21.9% | ||
| Q2 24 | 34.8% | 19.3% |
营业利润率ICUISTRL
| Q1 26 | — | 16.7% | ||
| Q4 25 | 1.0% | 15.9% | ||
| Q3 25 | 2.6% | 18.2% | ||
| Q2 25 | 1.9% | 17.0% | ||
| Q1 25 | 2.1% | 13.0% | ||
| Q4 24 | 6.0% | 12.5% | ||
| Q3 24 | 1.4% | 14.7% | ||
| Q2 24 | 1.3% | 12.5% |
净利率ICUISTRL
| Q1 26 | — | 11.6% | ||
| Q4 25 | -2.9% | 11.6% | ||
| Q3 25 | -0.6% | 13.4% | ||
| Q2 25 | 6.4% | 11.6% | ||
| Q1 25 | -2.6% | 9.2% | ||
| Q4 24 | -3.8% | 22.7% | ||
| Q3 24 | -5.6% | 10.3% | ||
| Q2 24 | -3.6% | 8.9% |
每股收益（稀释后）ICUISTRL
| Q1 26 | — | $3.09 | ||
| Q4 25 | $-0.63 | $2.82 | ||
| Q3 25 | $-0.14 | $2.97 | ||
| Q2 25 | $1.43 | $2.31 | ||
| Q1 25 | $-0.63 | $1.28 | ||
| Q4 24 | $-0.97 | $3.63 | ||
| Q3 24 | $-1.35 | $1.97 | ||
| Q2 24 | $-0.88 | $1.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $511.9M |
| 总债务越低越好 | — | $287.5M |
| 股东权益账面价值 | $2.1B | $1.2B |
| 总资产 | $4.1B | $2.8B |
| 负债/权益比越低杠杆越低 | — | 0.24× |
8季度趋势，按日历期对齐
现金及短期投资ICUISTRL
| Q1 26 | — | $511.9M | ||
| Q4 25 | — | $390.7M | ||
| Q3 25 | — | $306.4M | ||
| Q2 25 | — | $699.4M | ||
| Q1 25 | — | $638.6M | ||
| Q4 24 | $308.6M | $664.2M | ||
| Q3 24 | $312.5M | $648.1M | ||
| Q2 24 | $302.6M | $540.0M |
总债务ICUISTRL
| Q1 26 | — | $287.5M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ICUISTRL
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.1B | $1.1B | ||
| Q2 25 | $2.1B | $881.7M | ||
| Q1 25 | $2.0B | $805.4M | ||
| Q4 24 | $2.0B | $808.1M | ||
| Q3 24 | $2.0B | $716.5M | ||
| Q2 24 | $2.0B | $670.7M |
总资产ICUISTRL
| Q1 26 | — | $2.8B | ||
| Q4 25 | $4.1B | $2.6B | ||
| Q3 25 | $4.1B | $2.6B | ||
| Q2 25 | $4.1B | $2.2B | ||
| Q1 25 | $4.2B | $2.0B | ||
| Q4 24 | $4.2B | $2.0B | ||
| Q3 24 | $4.3B | $2.0B | ||
| Q2 24 | $4.3B | $2.0B |
负债/权益比ICUISTRL
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $165.6M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | — |
| 自由现金流率自由现金流/营收 | 6.6% | — |
| 资本支出强度资本支出/营收 | 4.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 1.73× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUISTRL
| Q1 26 | — | $165.6M | ||
| Q4 25 | $60.6M | $186.1M | ||
| Q3 25 | $56.7M | $83.6M | ||
| Q2 25 | $11.2M | $85.4M | ||
| Q1 25 | $51.3M | $84.9M | ||
| Q4 24 | $40.2M | $174.3M | ||
| Q3 24 | $36.1M | $152.3M | ||
| Q2 24 | $82.0M | $121.0M |
自由现金流ICUISTRL
| Q1 26 | — | — | ||
| Q4 25 | $36.0M | $159.7M | ||
| Q3 25 | $27.6M | $64.0M | ||
| Q2 25 | $-8.5M | $72.1M | ||
| Q1 25 | $36.7M | $67.0M | ||
| Q4 24 | $16.1M | $158.6M | ||
| Q3 24 | $16.2M | $138.3M | ||
| Q2 24 | $62.5M | $92.1M |
自由现金流率ICUISTRL
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 21.1% | ||
| Q3 25 | 5.1% | 9.3% | ||
| Q2 25 | -1.5% | 11.7% | ||
| Q1 25 | 6.1% | 15.5% | ||
| Q4 24 | 2.6% | 31.8% | ||
| Q3 24 | 2.7% | 23.3% | ||
| Q2 24 | 10.5% | 15.8% |
资本支出强度ICUISTRL
| Q1 26 | — | 2.4% | ||
| Q4 25 | 4.6% | 3.5% | ||
| Q3 25 | 5.4% | 2.9% | ||
| Q2 25 | 3.6% | 2.2% | ||
| Q1 25 | 2.4% | 4.2% | ||
| Q4 24 | 3.8% | 3.1% | ||
| Q3 24 | 3.4% | 2.4% | ||
| Q2 24 | 3.3% | 5.0% |
现金转化率ICUISTRL
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 2.12× | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | 0.32× | 1.20× | ||
| Q1 25 | — | 2.15× | ||
| Q4 24 | — | 1.54× | ||
| Q3 24 | — | 2.48× | ||
| Q2 24 | — | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
STRL
| E-Infrastructure Solutions | $597.7M | 72% |
| Transportation Solutions | $132.9M | 16% |
| Building Solutions | $95.1M | 12% |
